Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MiNK Therapeutics, Inc. (INKT)
USD11.09
-0.32 (-2.80%)
US NASDAQ NASDAQ 100
Healthcare Biotechnology
Address
149 Fifth Avenue 10010
New York City, NY, US
New York City, NY, US
CEO
Jennifer S. Buell
Website
minktherapeutics.com
IPO
2021-10-15
CIK 1840229 ISIN US6036932019
Description
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| NASDAQ 100 | 2000-12-18 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD11.09
-0.32 (-2.80%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
41.1K
Beta
0.47
Float Shares
1.19M
Free Float %
24.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.00% | -2.63% | -24.56% | -4.11% | -10.67% | -3.86% | +41.05% | -40.44% | -91.07% | -91.07% | -91.07% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
11.09
Low
35.00
+215.6%
Consensus
35.00
+215.6%
Median
35.00
+215.6%
High
35.00
+215.6%
DCF (Unlevered)
3,126.92
+28,095.8%
DCF (Levered)
3,127.67
+28,102.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
35.00
+215.6%
|
| All Time | 1 |
35.00
+215.6%
|
Quality scores
Altman Z-Score
-18.96
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-4.6% Q1'26: +18.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+10.5% Q1'26: +21.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.42× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
125.0K
125.0K – 125.0K
|
4.40M
4.40M – 4.40M
+3,420.0% YoY
|
18.36M
18.36M – 18.36M
+317.2% YoY
|
46.28M
46.28M – 46.28M
+152.1% YoY
|
85.00M
85.00M – 85.00M
+83.7% YoY
|
| EBITDA |
-10.57M
|
-12.31M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-10.78M
|
-12.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-10.78M
est: -14.09M (+23.4%)
|
-12.49M
est: -13.11M (+4.7%)
|
-13.92M
-14.92M – -12.92M
-6.2% YoY
|
-14.73M
-15.29M – -14.18M
-5.8% YoY
|
-5.42M
-8.65M – -2.20M
+63.2% YoY
|
-7.96M
-7.96M – -7.96M
-46.9% YoY
|
5.59M
5.59M – 5.59M
+170.2% YoY
|
| SGA |
4.10M
|
6.73B
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.90
est: -3.65 (+20.5%)
|
-2.93
est: -3.07 (+4.6%)
|
-3.27
-3.49 – -3.03
-6.4% YoY
|
-3.45
-3.58 – -3.32
-5.7% YoY
|
-1.27
-2.02 – -0.52
+63.2% YoY
|
-1.87
-1.87 – -1.87
-46.9% YoY
|
1.31
1.31 – 1.31
+170.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.35B
OE per share TTM
-339.27
Owner's Yield
-2,998.06%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
667.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
8
Total invested
184.8K
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Agenus Inc. (“Agenus”) | 26.33M | 79.80% | 26.33M | — | 26.33M | — | CO | — | 2021-10-28 | ↗ |
| 2 | GKCC, LLC | 4.64M | 11.79% | 4.64M | — | 4.64M | — | PN | Delaware | 2024-05-22 | ↗ |
| 3 | Garo H. Armen | 3.51M | 9.68% | 3.51M | — | 3.51M | 11.00 | IN | — | 2024-02-14 | ↗ |
| 4 | The Garo H. Armen Grantor Retained Annuity Trust Agreement 2023 #1 | 657.3K | 1.90% | 657.3K | — | 657.3K | 11.00 | OO | — | 2024-02-14 | ↗ |
| 5 | The Garo H. Armen Grantor Retained Annuity Trust Agreement 2022 #1 | 342.7K | 0.99% | 342.7K | — | 342.7K | 11.00 | OO | — | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
8
-16 vs prev Q
New positions
2
Closed positions
18
Increased
3
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | HORIZON FINANCIAL SERVICES, LLC | 160.00 +160.0 (+100.0%) | 1.8K +1.8K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.001 pp | USD11.15 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 74.4K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 183.4K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.3K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 3.5K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 258.46 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 598.0K | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.3K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 713.08 | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 288.36 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 31.78 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.86
Neutral
Ratio by volume
3.00
Bullish
Buys
6
Sells
7
Shares acquired
103.1K
Shares disposed
12.0K
Cash buys
—
Cash sales
6.00
Net activity
+91,030
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-13 | Orilall Melissa | Officer | — | — | Common Stock | 0 | 0.00 | — | 222 | I | ↗ |
| 2026-03-13 | Charette Austin | Officer | — | — | Common Stock | 0 | 0.00 | — | 40 | D | ↗ |
| 2026-03-10 | Ryan Barbara | Director | S-Sale | D | Common Stock | 300 | 15.28 | 4.6K | 21,406 | D | ↗ |
| 2026-03-09 | Ryan Barbara | Director | S-Sale | D | Common Stock | 200 | 10.17 | 2.0K | 21,706 | D | ↗ |
| 2026-03-02 | Ryan Barbara | Director | S-Sale | D | Common Stock | 100 | 10.83 | 1.1K | 21,906 | D | ↗ |
| 2026-02-27 | Ryan Barbara | Director | S-Sale | D | Common Stock | 400 | 10.86 | 4.3K | 22,006 | D | ↗ |
| 2026-01-02 | WIINBERG ULF | Director | A-Award | A | Stock Option (Right to Buy) | 5,395 | 11.12 | 60.0K | 5,395 | D | ↗ |
| 2026-01-02 | Ryan Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 5,395 | 11.12 | 60.0K | 5,395 | D | ↗ |
| 2026-01-02 | Corvese Brian | Director | A-Award | A | Stock Option (Right to Buy) | 5,395 | 11.12 | 60.0K | 5,395 | D | ↗ |
| 2026-01-02 | Buell Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 11.12 | 556.0K | 50,000 | D | ↗ |
| 2026-01-02 | Behner Peter | Director | A-Award | A | Stock Option (Right to Buy) | 5,395 | 11.12 | 60.0K | 5,395 | D | ↗ |
| 2025-12-01 | WIINBERG ULF | Director | A-Award | A | Common Stock | 1,263 | 11.09 | 14.0K | 20,234 | D | ↗ |
| 2025-12-01 | Ryan Barbara | Director | A-Award | A | Common Stock | 1,601 | 11.09 | 17.8K | 22,406 | D | ↗ |
| 2025-12-01 | Kadlec Robert Peter | Director | A-Award | A | Common Stock | 1,218 | 11.09 | 13.5K | 19,126 | D | ↗ |
| 2025-12-01 | Holcomb John Bradley | Director | A-Award | A | Common Stock | 1,128 | 11.09 | 12.5K | 1,128 | D | ↗ |
| 2025-12-01 | Corvese Brian | Director | A-Award | A | Common Stock | 1,612 | 11.09 | 17.9K | 50,053 | D | ↗ |
| 2025-12-01 | Behner Peter | Director | A-Award | A | Common Stock | 1,466 | 11.09 | 16.3K | 20,115 | D | ↗ |
| 2025-09-23 | Holcomb John Bradley | Director | A-Award | A | Stock Option (Right to Buy) | 4,174 | 14.92 | 62.3K | 4,174 | D | ↗ |
| 2025-09-09 | WIINBERG ULF | Director | A-Award | A | Stock Option (Right to Buy) | 3,225 | 15.36 | 49.5K | 3,225 | D | ↗ |
| 2025-09-09 | Ryan Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 3,225 | 15.36 | 49.5K | 3,225 | D | ↗ |
| 2025-09-09 | Kadlec Robert Peter | Director | A-Award | A | Stock Option (Right to Buy) | 3,225 | 15.36 | 49.5K | 3,225 | D | ↗ |
| 2025-09-09 | Corvese Brian | Director | A-Award | A | Stock Option (Right to Buy) | 3,225 | 15.36 | 49.5K | 3,225 | D | ↗ |
| 2025-09-09 | Buell Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 15.36 | 768.0K | 50,000 | D | ↗ |
| 2025-09-09 | Behner Peter | Director | A-Award | A | Stock Option (Right to Buy) | 3,225 | 15.36 | 49.5K | 3,225 | D | ↗ |
| 2025-09-02 | WIINBERG ULF | Director | A-Award | A | Common Stock | 1,011 | 13.86 | 14.0K | 18,971 | D | ↗ |
| 2025-09-02 | Ryan Barbara | Director | A-Award | A | Common Stock | 1,281 | 13.86 | 17.8K | 20,805 | D | ↗ |
| 2025-09-02 | Kadlec Robert Peter | Director | A-Award | A | Common Stock | 975 | 13.86 | 13.5K | 17,908 | D | ↗ |
| 2025-09-02 | Corvese Brian | Director | A-Award | A | Common Stock | 1,290 | 13.86 | 17.9K | 48,441 | D | ↗ |
| 2025-09-02 | Behner Peter | Director | A-Award | A | Common Stock | 1,173 | 13.86 | 16.3K | 18,649 | D | ↗ |
| 2025-06-02 | WIINBERG ULF | Director | A-Award | A | Common Stock | 1,953 | 7.17 | 14.0K | 17,960 | D | ↗ |
| 2025-06-02 | Ryan Barbara | Director | A-Award | A | Common Stock | 2,476 | 7.17 | 17.8K | 19,524 | D | ↗ |
| 2025-06-02 | Kadlec Robert Peter | Director | A-Award | A | Common Stock | 1,883 | 7.17 | 13.5K | 4,647 | D | ↗ |
| 2025-06-02 | Corvese Brian | Director | A-Award | A | Common Stock | 2,494 | 7.17 | 17.9K | 47,151 | D | ↗ |
| 2025-06-02 | Behner Peter | Director | A-Award | A | Common Stock | 2,267 | 7.17 | 16.3K | 17,476 | D | ↗ |
| 2025-03-03 | WIINBERG ULF | Director | A-Award | A | Common Stock | 1,593 | 8.79 | 14.0K | 16,007 | D | ↗ |
| 2025-03-03 | Ryan Barbara | Director | A-Award | A | Common Stock | 2,019 | 8.79 | 17.7K | 17,048 | D | ↗ |
| 2025-03-03 | Kadlec Robert Peter | Director | A-Award | A | Common Stock | 1,536 | 8.79 | 13.5K | 2,764 | D | ↗ |
| 2025-03-03 | Corvese Brian | Director | A-Award | A | Common Stock | 2,033 | 8.79 | 17.9K | 44,657 | D | ↗ |
| 2025-03-03 | Behner Peter | Director | A-Award | A | Common Stock | 1,849 | 8.79 | 16.3K | 15,209 | D | ↗ |
| 2024-12-01 | WIINBERG ULF | Director | A-Award | A | Common Stock | 20,476 | 0.73 | 14.9K | 144,181 | D | ↗ |
| 2024-12-01 | Ryan Barbara | Director | A-Award | A | Common Stock | 24,229 | 0.73 | 17.7K | 150,336 | D | ↗ |
| 2024-12-01 | Kadlec Robert Peter | Director | A-Award | A | Common Stock | 12,286 | 0.73 | 9.0K | 12,286 | D | ↗ |
| 2024-12-01 | Corvese Brian | Director | A-Award | A | Common Stock | 24,400 | 0.73 | 17.8K | 426,283 | D | ↗ |
| 2024-12-01 | Behner Peter | Director | A-Award | A | Common Stock | 20,987 | 0.73 | 15.3K | 133,634 | D | ↗ |
| 2024-10-30 | Kadlec Robert Peter | Director | A-Award | A | Stock Option | 41,745 | 0.72 | 30.1K | 41,745 | D | ↗ |
| 2024-09-03 | WIINBERG ULF | Director | A-Award | A | Common Stock | 18,295 | 0.82 | 15.0K | 123,705 | — | ↗ |
| 2024-09-03 | Ryan Barbara | Director | A-Award | A | Common Stock | 21,649 | 0.82 | 17.8K | 126,107 | — | ↗ |
| 2024-09-03 | Corvese Brian | Director | A-Award | A | Common Stock | 21,802 | 0.82 | 17.9K | 405,296 | — | ↗ |
| 2024-09-03 | Behner Peter | Director | A-Award | A | Common Stock | 18,753 | 0.82 | 15.4K | 109,234 | — | ↗ |
| 2024-06-03 | WIINBERG ULF | Director | A-Award | A | Common Stock | 15,077 | 0.99 | 14.9K | 105,410 | — | ↗ |
| 2024-06-03 | Ryan Barbara | Director | A-Award | A | Common Stock | 17,841 | 0.99 | 17.7K | 104,458 | — | ↗ |
| 2024-06-03 | Corvese Brian | Director | A-Award | A | Common Stock | 17,967 | 0.99 | 17.8K | 383,494 | — | ↗ |
| 2024-06-03 | Behner Peter | Director | A-Award | A | Common Stock | 15,454 | 0.99 | 15.3K | 90,481 | — | ↗ |
| 2024-03-01 | WIINBERG ULF | Director | A-Award | A | Common Stock | 15,790 | 0.95 | 15.0K | 90,333 | — | ↗ |
| 2024-03-01 | Ryan Barbara | Director | A-Award | A | Common Stock | 18,685 | 0.95 | 17.8K | 86,617 | — | ↗ |
| 2024-03-01 | Corvese Brian | Director | A-Award | A | Common Stock | 18,816 | 0.95 | 17.9K | 365,527 | — | ↗ |
| 2024-03-01 | Behner Peter | Director | A-Award | A | Common Stock | 16,185 | 0.95 | 15.4K | 75,027 | — | ↗ |
| 2024-01-16 | van Dijk Marcus Antonius | Officer | A-Award | A | Stock Option | 171,078 | 0.87 | 148.8K | 171,078 | — | ↗ |
| 2024-01-16 | Buell Jennifer | Officer | A-Award | A | Stock Option | 660,919 | 0.87 | 575.0K | 660,919 | — | ↗ |
| 2023-12-01 | WIINBERG ULF | Director | A-Award | A | Common Stock | 14,424 | 1.04 | 15.0K | 74,543 | — | ↗ |
| 2023-12-01 | Ryan Barbara | Director | A-Award | A | Common Stock | 17,068 | 1.04 | 17.8K | 67,932 | — | ↗ |
| 2023-12-01 | Corvese Brian | Director | A-Award | A | Common Stock | 17,188 | 1.04 | 17.9K | 346,711 | — | ↗ |
| 2023-12-01 | Behner Peter | Director | A-Award | A | Common Stock | 14,784 | 1.04 | 15.4K | 58,842 | — | ↗ |
| 2023-10-16 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 429 | 1.10 | 471.56 | 21,772,863 | — | ↗ |
| 2023-10-13 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 19,373 | 1.10 | 21.3K | 21,772,434 | — | ↗ |
| 2023-10-12 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 3,173 | 1.10 | 3.5K | 21,753,061 | — | ↗ |
| 2023-10-11 | Buell Jennifer | Director / Officer | J-Other | D | Common Stock | 695,750 | 0.00 | — | 232,165 | — | ↗ |
| 2023-10-04 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 15,001 | 1.09 | 16.4K | 21,749,888 | — | ↗ |
| 2023-10-03 | Buell Jennifer | Director / Officer | F-InKind | D | Common Stock | 65,000 | 0.94 | 61.4K | 927,915 | — | ↗ |
| 2023-10-02 | Buell Jennifer | Director / Officer | F-InKind | D | Common Stock | 58,550 | 1.04 | 61.2K | 992,915 | — | ↗ |
| 2023-09-29 | Buell Jennifer | Director / Officer | F-InKind | D | Common Stock | 25,000 | 1.15 | 28.8K | 1,051,465 | — | ↗ |
| 2023-09-27 | Buell Jennifer | Officer | M-Exempt | A | Common Stock | 695,750 | 0.00 | — | 1,076,465 | — | ↗ |
| 2023-09-01 | WIINBERG ULF | Director | A-Award | A | Common Stock | 9,590 | 1.46 | 14.0K | 60,119 | — | ↗ |
| 2023-09-01 | Ryan Barbara | Director | A-Award | A | Common Stock | 12,158 | 1.46 | 17.8K | 50,864 | — | ↗ |
| 2023-09-01 | Corvese Brian | Director | A-Award | A | Common Stock | 12,244 | 1.46 | 17.9K | 329,523 | — | ↗ |
| 2023-09-01 | Behner Peter | Director | A-Award | A | Common Stock | 10,531 | 1.46 | 15.4K | 44,058 | — | ↗ |
| 2023-09-01 | Baldoni John | Director | A-Award | A | Common stock | 9,846 | 1.46 | 14.4K | 41,193 | — | ↗ |
| 2023-08-29 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 29,678 | 1.52 | 45.0K | 21,734,887 | — | ↗ |
| 2023-08-28 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 12,808 | 1.45 | 18.6K | 21,705,209 | — | ↗ |
| 2023-08-24 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 170,244 | 1.54 | 262.9K | 21,692,401 | — | ↗ |
| 2023-06-14 | WIINBERG ULF | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 2.27 | 51.1K | 22,500 | — | ↗ |
| 2023-06-14 | Ryan Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 37,500 | 2.27 | 85.1K | 37,500 | — | ↗ |
| 2023-06-14 | Corvese Brian | Director | A-Award | A | Stock Option (Right to Buy) | 37,500 | 2.27 | 85.1K | 37,500 | — | ↗ |
| 2023-06-14 | Behner Peter | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 2.27 | 51.1K | 22,500 | — | ↗ |
| 2023-06-14 | Baldoni John | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 2.27 | 51.1K | 22,500 | — | ↗ |
| 2023-06-01 | WIINBERG ULF | Director | A-Award | A | Common Stock | 7,955 | 1.76 | 14.0K | 50,706 | — | ↗ |
| 2023-06-01 | Ryan Barbara | Director | A-Award | A | Common Stock | 10,086 | 1.76 | 17.8K | 38,930 | — | ↗ |
| 2023-06-01 | Corvese Brian | Director | A-Award | A | Common Stock | 10,157 | 1.76 | 17.9K | 317,505 | — | ↗ |
| 2023-06-01 | Behner Peter | Director | A-Award | A | Common Stock | 8,736 | 1.76 | 15.4K | 33,721 | — | ↗ |
| 2023-06-01 | Baldoni John | Director | A-Award | A | Common stock | 8,168 | 1.76 | 14.4K | 31,528 | — | ↗ |
| 2023-05-11 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 23,361 | 1.43 | 33.3K | 21,640,473 | — | ↗ |
| 2023-05-10 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 22,065 | 1.51 | 33.3K | 21,617,112 | — | ↗ |
| 2023-05-05 | ARMEN GARO H | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-05 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 200 | 1.25 | 250.00 | 21,595,047 | — | ↗ |
| 2023-05-04 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 21,473 | 1.22 | 26.2K | 21,494,847 | — | ↗ |
| 2023-05-03 | AGENUS INC | 10% Owner | P-Purchase | A | Common Stock | 128,689 | 1.08 | 138.8K | 21,473,374 | — | ↗ |
| 2023-05-02 | ARMEN GARO H | Director | P-Purchase | A | Common Stock | 100,000 | 0.95 | 94.9K | 1,978,010 | — | ↗ |
| 2023-05-01 | AGENUS INC | 10% Owner | J-Other | D | Common Stock | 5,006,397 | 0.00 | — | 21,326,369 | — | ↗ |
| 2023-03-01 | WIINBERG ULF | Director | A-Award | A | Common Stock | 6,699 | 2.09 | 14.0K | 42,751 | — | ↗ |
| 2023-03-01 | Ryan Barbara | Director | A-Award | A | Common Stock | 8,493 | 2.09 | 17.8K | 28,844 | — | ↗ |
| 2023-03-01 | Corvese Brian | Director | A-Award | A | Common Stock | 8,553 | 2.09 | 17.9K | 307,348 | — | ↗ |
| 2023-03-01 | Behner Peter | Director | A-Award | A | Common Stock | 7,357 | 2.09 | 15.4K | 24,985 | — | ↗ |
| 2023-03-01 | Baldoni John | Director | A-Award | A | Common stock | 6,878 | 2.09 | 14.4K | 23,360 | — | ↗ |
| 2023-01-16 | ARMEN GARO H | Director | A-Award | A | Stock Option | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2023-01-09 | van Dijk Marcus Antonius | Officer | A-Award | A | Stock Option | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2023-01-09 | Buell Jennifer | Officer | A-Award | A | Stock Option | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2022-12-01 | WIINBERG ULF | Director | A-Award | A | Common Stock | 5,364 | 2.61 | 14.0K | 36,052 | — | ↗ |
| 2022-12-01 | Ryan Barbara | Director | A-Award | A | Common Stock | 6,801 | 2.61 | 17.8K | 20,351 | — | ↗ |
| 2022-12-01 | Corvese Brian | Director | A-Award | A | Common Stock | 6,849 | 2.61 | 17.9K | 298,795 | — | ↗ |
| 2022-12-01 | Behner Peter | Director | A-Award | A | Common Stock | 5,891 | 2.61 | 15.4K | 17,628 | — | ↗ |
| 2022-12-01 | Baldoni John | Director | A-Award | A | Common stock | 5,508 | 2.61 | 14.4K | 16,482 | — | ↗ |
| 2022-09-15 | WIINBERG ULF | Director | A-Award | A | Common Stock | 10,688 | 2.62 | 28.0K | 10,688 | — | ↗ |
| 2022-09-15 | Ryan Barbara | Director | A-Award | A | Common Stock | 13,550 | 2.62 | 35.5K | 13,550 | — | ↗ |
| 2022-09-15 | Corvese Brian | Director | A-Award | A | Common Stock | 13,646 | 2.62 | 35.8K | 13,646 | — | ↗ |
| 2022-09-15 | Behner Peter | Director | A-Award | A | Common Stock | 11,737 | 2.62 | 30.8K | 11,737 | — | ↗ |
| 2022-09-15 | Baldoni John | Director | A-Award | A | Common stock | 10,974 | 2.62 | 28.8K | 10,974 | — | ↗ |
| 2022-07-18 | WIINBERG ULF | Director | P-Purchase | A | Common Stock | 3,339 | 1.33 | 4.4K | 281,639 | — | ↗ |
| 2022-03-09 | WIINBERG ULF | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-03-09 | Ryan Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 2.89 | 72.3K | 25,000 | — | ↗ |
| 2022-03-09 | Corvese Brian | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 2.89 | 72.3K | 25,000 | — | ↗ |
| 2022-03-09 | Behner Peter | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-03-09 | Baldoni John | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-01-21 | van Dijk Marcus Antonius | Officer | A-Award | A | Stock Option (Right to Buy) | 62,500 | 3.12 | 195.0K | 62,500 | — | ↗ |
| 2022-01-21 | Buell Jennifer | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 679,800 | 3.12 | 2.12M | 679,800 | — | ↗ |
| 2021-12-31 | ARMEN GARO H | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-19 | AGENUS INC | 10% Owner | C-Conversion | D | Convertible Promissory Note | 5,451,958 | 0.00 | — | 0 | — | ↗ |
| 2021-10-13 | van Dijk Marcus Antonius | Officer | — | D | Stock Option (Right to Buy) | 20,872 | 0.02 | 417.44 | 0 | — | ↗ |
| 2021-10-13 | WIINBERG ULF | Director | — | D | Stock Option (Right to Buy) | 27,830 | 0.02 | 556.60 | 0 | — | ↗ |
| 2021-10-13 | Ryan Barbara | Director | — | D | Stock Option (Right to Buy) | 41,745 | 3.03 | 126.5K | 0 | — | ↗ |
| 2021-10-13 | KLASKIN CHRISTINE M | Officer | — | D | Common Stock | 0 | 0.00 | — | 55,660 | — | ↗ |
| 2021-10-13 | FLAMENBAUM WALTER MD | Director | — | D | Stock Option (Right to Buy) | 41,745 | 3.03 | 126.5K | 0 | — | ↗ |
| 2021-10-13 | Corvese Brian | Director | — | D | Stock Option (Right to Buy) | 208,725 | 0.01 | 2.1K | 0 | — | ↗ |
| 2021-10-13 | Buell Jennifer | Director / Officer | — | D | Restricted Stock Units | 695,750 | 0.00 | — | 0 | — | ↗ |
| 2021-10-13 | Behner Peter | Director | — | D | Stock Option (Right to Buy) | 41,745 | 3.03 | 126.5K | 0 | — | ↗ |
| 2021-10-13 | Baldoni John | Director | — | D | Stock Option (Right to Buy) | 41,745 | 3.03 | 126.5K | 0 | — | ↗ |
| 2021-10-13 | ARMEN GARO H | Director | — | D | Stock Option (Right to Buy) | 834,900 | 3.03 | 2.53M | 0 | — | ↗ |
| 2021-10-13 | AGENUS INC | Director | — | D | Convertible Promissory Note | 5,451,958 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
4.97M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jennifer S. Buell, Ph.D. President and Chief Executive Officer | 448.0K | 350.0K | — | 1.28M | — | 5.7K | 2.09M | 61.51% | ↗ |
| 2 | 2025 | Christine M. Klaskin Consultant and Former Treasurer | 29.8K | — | — | — | — | — | 29.8K | 0.00% | ↗ |
| 3 | 2024 | Jennifer S. Buell, Ph.D. President and Chief Executive Officer | 448.0K | 280.0K | — | 345.0K | — | 5.7K | 1.08M | 31.98% | ↗ |
| 4 | 2024 | Marc van Dijk, Ph.D. Strategic Consultant and Scientific Advisory Board Member; Former Chief Scientific Officer | 341.8K | — | — | 10.4K | — | 50.3K | 402.5K | 2.57% | ↗ |
| 5 | 2024 | Christine M. Klaskin Consultant and Former Treasurer | 29.8K | — | — | — | — | — | 29.8K | 0.00% | ↗ |
| 6 | 2024 | Christine M. Klaskin Treasurer | 29.8K | — | — | — | — | — | 29.8K | 0.00% | ↗ |
| 7 | 2023 | Jennifer S. Buell, Ph.D. President and Chief Executive Officer | 451.0K | 460.0K | 1.01M | 885.0K | — | 5.7K | 2.81M | 67.35% | ↗ |
| 8 | 2023 | Marc van Dijk, Ph.D. Strategic Consultant and Scientific Advisory Board Member; Former Chief Scientific Officer | 334.0K | 119.1K | 39.9K | 26.6K | — | 49.3K | 568.8K | 11.69% | ↗ |
| 9 | 2023 | Marc van Dijk, Ph.D. Chief Scientific Officer | 334.0K | 75.0K | 39.9K | 26.6K | — | 49.3K | 524.8K | 12.67% | ↗ |
| 10 | 2023 | Christine M. Klaskin Treasurer | 29.6K | — | — | — | — | — | 29.6K | 0.00% | ↗ |
| 11 | 2022 | Jennifer S. Buell, Ph.D. President and Chief Executive Officer | 424.3K | 383.3K | — | 3.06M | — | 5.1K | 3.87M | 79.01% | ↗ |
| 12 | 2022 | Marc van Dijk, Ph.D. Chief Scientific Officer | 252.3K | 79.9K | — | 281.3K | — | 37.7K | 651.2K | 43.19% | ↗ |
| 13 | 2022 | Christine M. Klaskin Treasurer | 27.2K | — | — | — | — | — | 27.2K | 0.00% | ↗ |
| 14 | 2021 | Jennifer S. Buell, Ph.D. President and Chief Executive Officer | 232.5K | — | 2.11M | 1.07M | — | — | 3.89M | 81.69% | ↗ |
| 15 | 2021 | Patrick N. Jordan Vice President of Business Operations | 360.0K | 94.5K | — | 53.5K | — | 7.1K | 515.2K | 10.39% | ↗ |
| 16 | 2021 | Marc van Dijk, Ph.D. Chief Scientific Officer | — | — | — | 107.1K | — | — | 107.1K | 100.00% | ↗ |
| 17 | 2021 | Christine M. Klaskin Treasurer | 20.0K | — | — | — | — | — | 20.0K | 0.00% | ↗ |
| 18 | 2020 | Patrick N. Jordan Vice President of Business Operations | 150.0K | — | 200.00 | — | — | 4.5K | 154.7K | 0.13% | ↗ |
| 19 | 2020 | Jennifer S. Buell, Ph.D. President and Chief Executive Officer | — | — | — | 917.00 | — | — | 917.00 | 100.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jennifer S. Buell | Co-Founder, President, CEO & Director | 803.7K | — |
| Christine Klaskin | Treasurer and Principal Financial & Accounting Officer | 29.8K | female |
| Austin Charette | Principal Accounting Officer | — | male |
| Melissa Orilall | Principal Financial Officer | — | female |
| Terese C. Hammond | Head of Inflammatory & Pulmonary Diseases | — | female |
| Garo H. Armen | Executive Chairman | — | — |
| Eleni Chantzoura | Director & Head of Discovery | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INKT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
